Interleukin-4-dependent production of PPAR-γ ligands in macrophages by 12/15-lipoxygenase

Tontonoz, P., Hu, E. & Spiegelman, B. M. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell 79, 1147–1156 (1994).

Lehmann, J. M.et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor-γ (PPARγ). J. Biol. Chem. 270, 12953–12956 (1995).

Willson, T. M.et al. The structure–activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones. J. Med. Chem. 39, 665–668 (1996).

Tontonoz, P., Nagy, L., Alvarez, J. G. A., Thomazy, V. A. & Evans, R. M. PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93, 241–252 (1998).

Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J. & Glass, C. K. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 391, 79–82 (1998).

Jiang, C., Ting, A. T. & Seed, B. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 391, 82–86 (1998).

Kliewer, S. A.et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ. Proc. Natl Acad. Sci. USA 94, 4318–4323 (1997).

Kliewer, S. A.et al. Aprostaglandin J2metabolite binds peroxisome prolifator-activated receptorγ and promotes adipocyte differentiation. Cell 83, 813–819 (1995).

Forman, B. M.et al. 15-Deoxy-Δ12,14-prostaglandin J2is a ligand for the adipocyte determination factor PPARγ. Cell 83, 803–812 (1995).

Nagy, L., Tontonoz, P., Alvarez, J. G. A., Chen, H. & Evans, R. M. Oxidized LDL regulates macrophage gene expression through ligand activation of PPAR-γ. Cell 93, 229–240 (1998).

Conrad, D. J., Kuhn, H., Mulkins, M., Highland, E. & Sigal, E. Specific inflammatory cytokines regulate the expression of human monocyte 15-lipoxygenase. Proc. Natl Acad. Sci. USA 89, 217–221 (1992).

Ricote, M.et al. Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc. Natl Acad. Sci. USA 95, 7614–7619 (1998).

Zhu, Y.et al. Structural organization of mouse peroxisome proliferator-activated receptor γ (mPPAR γ) gene: alternative promoter use and different splicing yield two mPPAR γ isoforms. Proc. Natl Acad. Sci. USA 92, 7921–7925 (1995).

Fajas, L., Fruchart, J. C. & Auwerx, J. PPARγ3 mRNA: a distinct PPARγ mRNA subtype transcribed from an independent promoter. FEBS Lett. 438, 55–60 (1998).

Yamamoto, S. Mammalian lipoxygenases: molecular structure and functions. Biochem. Biophys. Res. Commun. 1128, 117–131 (1992).

van Leyen, K., Duvoisin, R. M., Engelhardt, H. & Wiedmann, M. Afunction for lipoxygenase in programmed organelle degradation. Nature 395, 392–395 (1998).

Rankin, S. M., Parthasarathy, S. & Steinberg, D. Evidence for a dominant role of lipoxygenase(s) in the oxidation of LDL by mouse peritoneal macrophages. J. Lipid Res. 32, 449–456 (1991).

Benz, D. J.et al. Enhanced levels of lipoperoxides in low density lipoproteins incubated with murine fibroblasts expressing high levels of human 15-lipoxygenase. J. Biol. Chem. 270, 5191–5197 (1995).

Funk, C. D. The molecular biology of mammalian lipoxygenases and the quest for eicosanoid functions using lipoxygenase-deficient mice. Biochim. Biophys. Acta 1304, 65–84 (1996).

Kuhn, H. Biosynthesis, metabolization and biological importance of the primary 15-lipoxygenase metabolites 15-hydro(pero)xy-5Z,8Z,11Z,13E-eicosatetraenoic acid and 13-hydro(pero)xy-9Z,11E-octadecadienoic acid. Prog. Lipid Res. 35, 203–226 (1996).

Heydeck, D.et al. Interleukin-4 and -13 induce upregulation of the murine macrophage 12/15-lipoxygenase activity: evidence for the involvement of transcription factor STAT6. Blood 92, 2503–2510 (1998).

Scheidegger, K. J., Butler, S. & Witztum, J. L. Angiotensin II increases macrophage-mediated modification of low density lipoprotein via a lipoxygenase-dependent pathway. J. Biol. Chem. 272, 21609–21615 (1997).

Bogdan, C., Vodovotz, Y., Paik, J., Xie, Q.-W. & Nathan, C. Mechanism of suppression of nitric oxide synthase expression by interleukin-4 in primary mouse macrophages. J. Leukocyte Biol. 55, 227–233 (1994).

Yesner, L. M., Huh, H. Y., Pearce, S. F. & Silverstein, R. L. Regulation of monocyte CD36 and thrombospondin-1 expression by soluble mediators. Arterioscler. Thromb. Vasc. Biol. 16, 1019–1025 (1996).

Yamada, Y., Doi, T., Hamakubo, T. & Kodama, T. Scavenger receptor family proteins: roles for atherosclerosis, host defence and disorders of the central nervous system. Cell. Mol. Life Sci. 54, 628–640 (1998).

Endemann, G.et al. CD36 is a receptor for oxidized low density lipoprotein. J. Biol. Chem. 268, 11811–11816 (1993).

Savill, J. S., Hogg, N., Ren, Y. & Haslett, C. Thrombospondin cooperates with CD36 and the vitronectin receptor in macrophage recognition of neutrophils undergoing apoptosis. J. Clin. Invest. 90, 1513–1522 (1992).

Sun, D. & Funk, C. D. Disruption of 12/15-lipoxygenase expression in peritoneal macrophages. J. Biol. Chem. 271, 24055–24062 (1996).

Nolte, R. T.et al. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ. Nature 395, 137–143 (1998).

Sigal, E. C., Craik, C. S. & Highland, E. Molecular cloning and primary structure of human 15-lipoxygenase. Biochem. Biophys. Res. Commun. 157, 457–464 (1988).